top of page

Bharathi Chundi, MDS

Content writer – Clinical

Dr. Bharathi is working as a clinical content ambassador in Rhenix life sciences. Her areas of specialization include relief of immediate tooth pain. Due to her keen interest in the research field, she worked as a freelance writer and associated with various research projects at NTR University of Health Sciences.

She completed her MDS (Master of Dental Surgery) from Krishnadevaraya Dental College & Hospital, Bangalore in the year 2018 and her BDS (Bachelor of Dental Surgery) from Government Dental College & Hospital, Vijayawada, 2013. She also did her Intermediate schooling at Ratnam residential school and College, Nellore. Apart from her post-graduation, she did Oral Implantology and BLS (Basic Life Sciences) courses. She also currently has 4 publications and 2 under peer review.

While she strives to work hard in this fast-paced and highly competitive environment without compromising on productivity and at the same time, she would like to explore new skills and technologies in this research field to update her knowledge and improve her efficiency.

Stories

Summary "High frequency of psychosis in late-stage Parkinson's disease."

Parkinson’s disease (PD) is a neurological disorder observed mostly in elderly individuals. The symptoms include tremors, muscle stiffness, slow motion, and loss of balance. It is caused when neurons of the basal ganglia region...

Parkinson's disease

Summary "Expression of   CD133 cancer stems cell marker in IDH-mutant and IDH-wild type (isocitrate dehydrogenase) astrocytoma."

Astrocytoma is a tumor that arises from the astrocytes. They belong to a group called glial cells, the supporting cells seen in the central nervous system. They are specifically called astrocytes when...

Astrocytoma

Summary "Somatostatin receptor theranostics for refractory Meningiomas."

Meningiomas are non-cancerous lesions that arises from the membranes surrounding the brain and the spinal cord. They contribute to around 30% of the initial brain tumors and they are associated with different clinical...

Meningiomas

Summary "The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung  squamous cell carcinoma: A real-world retrospective cohort study."

Lung cancer is the leading cause of cancer-related death. The most frequent forms of treatment for lung cancer include chemotherapy, radiotherapy, and surgery. The most common type of lung cancer is non-small cell lung cancer...

Lung Cancer

Videos

High frequency of psychosis in late-stage Parkinson's disease | Cell talk

Parkinson’s disease (PD) is a neurological disorder observed mostly in elderly individuals. The symptoms include tremors, muscle stiffness, slow motion, and loss of balance. It is caused when neurons of the basal ganglia region...

Expression of   CD133 cancer stem cell marker in IDH-mutant and IDH-wild type (isocitrate dehydrogenase) astrocytoma | Cell talk

Astrocytoma is a tumor that arises from the astrocytes. They belong to a group called glial cells, the supporting cells seen in the central nervous system. They are specifically called astrocytes when they are restricted to the brain or spinal...

Somatostatin receptor theranostics for refractory Meningiomas | Cell talk

Meningiomas are non-cancerous lesions that arise from the membranes surrounding the brain and the spinal cord. They contribute to around 30% of the initial brain tumors and they are associated with different clinical outcomes. About 80% of...

The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung  squamous cell carcinoma: A real-world retrospective cohort study | Cell talk

Lung cancer is the leading cause of cancer-related death. The most frequent forms of treatment for lung cancer include chemotherapy, radiotherapy, and surgery. The most common type of lung cancer is non-small cell lung cancer (NSCLC) which contributes to...

Connecting Dots

Get the latest updates

Join Cell talk!

Subscribe us today & receive latest updates on your mail !

bottom of page